Coverage of "Life sciences" on cryptobo.eu: the stories and the context behind them.
Thermo Fisher Scientific reported Q2 adjusted EPS of $6.03 against a $5.72 estimate and revenue of $11.99 billion, beating forecasts and prompting management to raise its full-year 2026 guidance. The result directly counters the sector anxiety that followed Danaher's weak outlook earlier this week.
